Table 3.
Clinical variables | Gene | Ratio | Testing ball. acc. | p-value | Cross validation consistency | |
---|---|---|---|---|---|---|
Male/female |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
1 |
0.5056 |
0.8506 |
10/10 |
|
Race (caucasian/ no caucasian) |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.0909 |
0.3909 |
0.9915 |
10/10 |
|
Age |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9889 |
0.5312 |
0.6870 |
10/10 |
|
Age for diagnosis |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.8804 |
0.4100 |
0.9989 |
10/10 |
|
Onset of symptoms |
geral |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.7526 |
0.4286 |
0.9945 |
10/10 |
digestive |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9737 |
0.4614 |
0.9698 |
10/10 |
|
pulmonary |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.7935 |
0.5022 |
0.8566 |
10/10 |
|
Clinical scores |
Bhalla |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9552 |
0.6824 |
0.0080# |
10/10 |
Kanga |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9571 |
0.5131 |
0.8165 |
10/10 |
|
Shwachman-Kulczycki |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9 |
0.5562 |
0.5474 |
10/10 |
|
Body mass index |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
3.45 |
0.5484 |
0.6260 |
10/10 |
|
Sputum’s microbiology |
A. xylosoxidans |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.1118 |
0.4617 |
0.9418 |
10/10 |
P. aeruginosa mucoid |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.7379 |
0.5505 |
0.5507 |
10/10 |
|
P. aeruginosa no mucoid |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
1.2949 |
0.4151 |
0.9951 |
10/10 |
|
S. aureus |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
3.7105 |
0.5094 |
0.8317 |
6/10 |
|
B. cepacia |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.1548 |
0.5277 |
0.7610 |
10/10 |
|
First isolated P. aeruginosa |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9552 |
0.4913 |
0.8903 |
7/10 |
|
Hemoglobin oxygen saturation in the blood |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9602 |
0.5312 |
0.6904 |
10/10 |
|
Spirometry |
FEV1 |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9848 |
0.4746 |
0.9448 |
10/10 |
FVC(%) |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.900 |
0.4437 |
0.9833 |
10/10 |
|
FEV1/FVC(%) |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9403 |
0.6426 |
0.0586 |
10/10 |
|
FEF25-75% |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.9848 |
0.5054 |
0.8447 |
10/10 |
|
Comorbidities |
Pancreatic insufficiency |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
3.977 |
0.5266 |
0.7486 |
10/10 |
Meconium ileus |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.1776 |
0.5401 |
0.6950 |
10/10 |
|
Nasal polyps |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.2292 |
0.5713 |
0.5139 |
10/10 |
|
Diabetes mellitus |
CFTR*GCLC*GSTP1*GSTT1*GSTM1 |
0.2292 |
0.4527 |
0.9728 |
10/10 |
|
Osteoporosis | CFTR*GCLC*GSTP1*GSTT1*GSTM1 | 0.1959 | 0.3815 | 0.9988 | 10/10 |
GCLC glutamate-cysteine ligase catalytic subunit, GST glutathione S-transferase, Testing Ball. Acc. Testing Balance Accuracy, CFTRCystic Fibrosis Transmembrane Regulator, A. xylosoxidansAchromobacter xylosoxidans, B. cepaciaBurkolderia cepacia, P. aeruginosaPseudomonas aeruginosa, S. aureusStaplylococcus aures, FEV1 forced expiratory volume in one second, FVC - forced vital capacity, FEF25-75% forced expiratory flow between 25 and 75% of CVF. 1. Severe variants to polymorphism: allele T, GCLC 129C>T polymorphism, allele G - GCLC-350A>G and GSTP1+313A>G polymorphisms, deletion allele GSTM1 and GSTT1 genes. # Association of GCLC-129C>T, GCLC-350A>G, GSTP1+313A>G, GSTM1 and GSTT1 genes deletion and mutations in the CFTR gene with the Bhalla Score, p: 0.0080. Statistical analysis performed by the MDR2.0 and MDRPT0.4.7 software.